QuantaMatrix Inc. (KOSDAQ:317690)

South Korea · Delayed Price · Currency is KRW

2,320.00

+40.00 (1.75%)

At close: Jul 10, 2026

-26.81% (1Y)

Market Cap	46.71B -20.3%
Revenue (ttm)	3.40B +24.6%
Net Income	-19.98B
EPS	-1,037.49
Shares Out	20.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,081
Open	2,260.00
Previous Close	2,280.00
Day's Range	2,260.00 - 2,400.00
52-Week Range	2,110.00 - 6,550.00
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About QuantaMatrix

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded i... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus

Founded 2010

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 317690

Full Company Profile

Financial Performance

In 2025, QuantaMatrix's revenue was 3.69 billion, an increase of 47.70% compared to the previous year's 2.50 billion. Losses were -19.46 billion, -3.51% less than in 2024.

Financial Statements